Expression of High Mobility Group Box - B1 (HMGB-1) and Matrix Metalloproteinase-9 (MMP-9) in Non-small Cell Lung Cancer (NSCLC)

Wang, Jingluan; Wu, Dawei; Cheng, Zhaozhong; Han, Weizhong; Xu, Sheng-Wei; Sun, Nina

doi:10.7314/apjcp.2014.15.12.4865

Cited by 22 publications

(25 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression level of MMP9 was positively correlated with HMGB1. 91 Tissue HMGB1 and NF-κB p65 protein expression was significantly higher in metastatic group, indicating that HMGB1, and NF-κB p65 expression may be related to NSCLC metastasis. 119 Serum Serum HMGB1 levels were significantly increased in patients with lung cancer than controls.…”

Section: A549 and H23mentioning

confidence: 84%

“…As reported that HMGB1 could induce epithelial‐mesenchymal transition through RAGE and the PI3 K/AKT/GSK3β/β‐catenin signaling pathway . Furthermore, HMGB1 interacts with RAGE and then induce tumor proliferation, invasion, and expression of matrix metallo proteinases (MMPs) by activating p44/p42, p38, and SAP/JNK MAPK . Inhibition of HMGB1‐RAGE interaction suppresses tumor growth and metastasis by activation of MAPK and NF‐κB pathway, which results in the expression of MMPs, such as MMP2 and MMP9 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of high‐mobility group protein box 1 in lung cancer

Wu¹,

Chen²,

Gong

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

High-mobility group protein box 1(HMGB1)is a ubiquitous highly conserved nuclear protein. Acting as a chromatin-binding factor, HMGB1 binds to DNA and plays an important role in stabilizing nucleosome formation, facilitating gene transcription, DNA repairing, inflammation, cell differentiation, and regulating the activity of steroid hormone receptors. Currently, HMGB1 is discovered to be related to development, progression, and targeted therapy of lung cancer, which makes it an attractive biomarker, and therapeutic target. This review aims to encapsulate the relationship between HMGB1 and lung cancer, suggesting that HMGB1 plays a pivotal role in initiation, development, invasion, metastasis, and prognosis of lung cancer.

show abstract

Section: A549 and H23mentioning

confidence: 84%

Section: Introductionmentioning

confidence: 99%

The role of high‐mobility group protein box 1 in lung cancer

Wu¹,

Chen²,

Gong

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…HMGB1 has been previously reported as a potential prognostic factor for NSCLC. 8 , 53 – 55 Naumnik et al 8 identified increased levels of HMGB1 in patients with advanced NSCLC undergoing chemotherapy. However, they concluded that HMGB1 concentration did not influence survival time following NSCLC treatment because there was no significant difference in HMGB1 levels before and after chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer

Niki¹,

Yokoi²,

Kurata³

et al. 2017

LCTT

View full text Add to dashboard Cite

BackgroundSeveral biomarkers have emerged as potential prognostic and predictive markers for non-small-cell lung cancer (NSCLC). Successful inhibition of angiogenesis with the antivascular endothelial growth factor antibody, bevacizumab, has improved the efficacy seen with standard cytotoxic therapy of NSCLC. However, despite such enhanced treatment strategies, the prognosis for patients with advanced NSCLC remains poor.Patients and methodsWe assessed potential biomarkers in 161 NSCLC patients and 42 control patients. Enzyme-linked immunosorbent assay methods were used to evaluate three biomarkers: platelet-derived microparticle (PDMP), high-mobility group box-1 (HMGB1), and plasminogen activator inhibitor-1 (PAI-1). We studied the effects of bevacizumab on the expression of these markers. We also analyzed the relationship of the newly designed risk factor (NDRF) to overall survival and disease-free survival. The NDRF classification of patients was determined from the levels of PDMP, HMGB1, and PAI-1. To determine the individual prognostic power of PDMP, HMGB1, and PAI-1, we evaluated associations between their levels and patient outcomes by Kaplan–Meier survival analysis in a derivation cohort.ResultsPDMP, HMGB1, and PAI-1 levels were higher in NSCLC patients compared with control patients. Notably, the difference in PDMP levels exhibited the strongest statistical significance (p<0.001). Multivariate analysis showed that HMGB1 and PAI-1 levels were significantly correlated with PDMP levels. Patients who received standard chemotherapy with bevacizumab exhibited significantly reduced levels of all three markers compared with patients who received standard chemotherapy. NDRF3 status (high levels of all three markers) was significantly correlated with a poor prognosis (p<0.05 for overall survival and disease-free survival).ConclusionOur results demonstrate that abnormal levels of PDMP, HMGB1, and PAI-1 are related to each other in NSCLC. Moreover, our findings suggest that the vascular complications associated with these markers may contribute to a poor prognosis for NSCLC patients.

show abstract

“…High-mobility group box 1 (HMGB1), one of the earliest identified and well characterized alarmin, belongs to the same HMG family, has been demonstrated to be an attractive biomarker in a number of malignant diseases including cervical, lung, breast, stomach, liver, pancreatic, colon, kidney, prostate, ovarian, skin, bone cancer, and leukemia [11][12][13][14]. Especially in patients with NSCLC, HMGB1 overexpression correlates with development, invasion, and metastasis [15][16][17][18]. However, few of investigators explore the role of HMGN1 in the tumor formation and development.…”

Section: Discussionmentioning

confidence: 99%

High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

The involvement of alarmin high-mobility group nucleosome-binding protein 1 (HMGN1) in non-small cell lung cancer (NSCLC) is unknown. To address the presence of HMGN1 in the serum of different stages of NSCLC patients and healthy controls, we enrolled a consecutive sample of adult serum at diagnosis and correlated it with clinicopathologic outcomes. A total of 100 NSCLC patients and 23 healthy volunteers were enrolled from January 2012 through December 2013. Serum HMGN1 levels were determined by enzyme-linked immunosorbent assay (ELISA). Additionally, HMGN1 levels in 50 NSCLC patients with early-stage disease who received curative pneumonectomy were correlated with survivals. Kaplan-Meier plots were used to analyze the data. The patients with NSCLC were characterized by significantly higher serum levels of HMGN1 (0.4585 ± 0.0640 ng/ml) compared to those in healthy controls (0.3578 ± 0.0304 ng/ml). The serum HMGN1 levels were 0.4027 ± 0.0271 ng/ml, 0.4604 ± 0.0328 ng/ml, 0.5408 ± 0.0459 ng/ml, and 0.4213 ± 0.0341 ng/ml in patients with TNM stages I, II, IV, and IV, respectively (p < 0.001). There were significant differences among four groups (p < 0.001). Additionally, a positive correlation between serum HMGN1 and tumor stage was found in local disease, while serum HMGN1 level in metastatic NSCLC patients was significantly decreased. The Kaplan-Meier plots showed that patients with high serum HMGN1 had a poorer overall survival (OS) after curative pneumonectomy than those with low serum HMGN1 (p = 0.019). Inflammation triggered by alarmins plays a role in NSCLC pathogenesis. HMGN1 can serve as a useful clinical parameter for evaluating disease progression and predicting the outcomes for early-stage patients with NSCLC undergoing pneumonectomy.

show abstract

Expression of High Mobility Group Box - B1 (HMGB-1) and Matrix Metalloproteinase-9 (MMP-9) in Non-small Cell Lung Cancer (NSCLC)

Cited by 22 publications

References 40 publications

The role of high‐mobility group protein box 1 in lung cancer

The role of high‐mobility group protein box 1 in lung cancer

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer

High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer

Contact Info

Product

Resources

About